2024
Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
Cohen J, Damsky W. Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency. New England Journal Of Medicine 2024, 391: 188-189. PMID: 38986070, DOI: 10.1056/nejmc2404977.Peer-Reviewed Original ResearchGranuloma Annulare Exhibits Mixed Immune and Macrophage Polarization Profiles with Spatial Transcriptomics
Mohanty C, Singh C, Daccache J, Damsky W, Kendziorski C, Yan D, Prasad A, Zhang D, Keenan T, Drolet B, Ahmad N, Shields B. Granuloma Annulare Exhibits Mixed Immune and Macrophage Polarization Profiles with Spatial Transcriptomics. Journal Of Investigative Dermatology 2024 PMID: 38844128, DOI: 10.1016/j.jid.2024.04.024.Peer-Reviewed Original ResearchGranuloma annulareGranulomatous inflammationFDA-approved therapiesInflammatory signaling cascadesImpact of GAIFN-gImmune cellsInterleukin-32Idiopathic conditionTh2 signalsAdaptive immunityInterstitial patternMacrophage activationGene expression changesMolecular driversQuality of lifeGenome-wide gene expression changesMacrophage polarizationGranulomaMacrophagesTissue remodelingInflammationTNF signalingLocal gene expression patternsSpatial transcriptomicsCharacterizing interstitial lung disease in patients with psoriasis: a cross-sectional analysis in the National Institutes of Health’s All of Us Research Program
Shaw V, Damsky W, Homer R, Cohen J. Characterizing interstitial lung disease in patients with psoriasis: a cross-sectional analysis in the National Institutes of Health’s All of Us Research Program. Clinical And Experimental Dermatology 2024, llae132. PMID: 38618708, DOI: 10.1093/ced/llae132.Peer-Reviewed Original ResearchElectronic health recordsUs Research ProgramCross-sectional analysisNational Institutes of HealthHealth recordsInstitutes of HealthConfounding variablesRate of interstitial lung diseaseMultivariate modelNational InstituteLung diseaseAssociationInterstitial lung diseaseConfoundingHealthORParticipantsParadoxical Psoriasis
Abdelghaffar M, Kottilil S, Murphy M, Cohen J, Damsky W. Paradoxical Psoriasis. Dermatologic Clinics 2024, 42: 471-480. PMID: 38796276, DOI: 10.1016/j.det.2024.02.011.Peer-Reviewed Original ResearchTreatment of prolonged drug reaction with eosinophilia and systemic symptoms syndrome with dupilumab using a molecularly-guided approach
Valido K, Patel V, Murphy M, Junejo M, Patel D, Deutsch A, Turner N, Zaki T, King B, Damsky W, Nelson C. Treatment of prolonged drug reaction with eosinophilia and systemic symptoms syndrome with dupilumab using a molecularly-guided approach. JAAD Case Reports 2024, 48: 49-53. PMID: 38774671, PMCID: PMC11107093, DOI: 10.1016/j.jdcr.2024.03.020.Peer-Reviewed Original ResearchDupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells
Bangert C, Alkon N, Chennareddy S, Arnoldner T, Levine J, Pilz M, Medjimorec M, Ruggiero J, Cohenour E, Jonak C, Damsky W, Griss J, Brunner P. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells. Nature Communications 2024, 15: 2839. PMID: 38565563, PMCID: PMC10987549, DOI: 10.1038/s41467-024-46540-0.Peer-Reviewed Original ResearchConceptsHead and neck dermatitisAtopic dermatitisNeck dermatitisT cellsHealthy control skinType 2 inflammationDupilumab treatmentImmune signaturesReceptor upregulationActivation markersClinical efficacyPunch biopsyHistopathological featuresDe novo appearanceIL-22Single-cell RNA sequencingDrug effectsDupilumabSide effectsControl skinDermatitisKeratinocyte activationUntreated ADTreatmentRNA sequencing
2023
Granuloma annulare is associated with an increased risk of hematologic malignancies: A multicenter cohort study using TriNetX
Garate D, Thang C, Damsky W, Rosenbach M, Golovko G, Wilkerson M, Barbieri J. Granuloma annulare is associated with an increased risk of hematologic malignancies: A multicenter cohort study using TriNetX. Journal Of The American Academy Of Dermatology 2023, 90: 862-864. PMID: 38147901, DOI: 10.1016/j.jaad.2023.12.028.Peer-Reviewed Original ResearchRetrospective assessment of immunologic and histologic heterogeneity in granuloma annulare by cytokine staining
Hwang E, Lee T, Okifo K, Murphy M, Damsky W. Retrospective assessment of immunologic and histologic heterogeneity in granuloma annulare by cytokine staining. International Journal Of Dermatology 2023, 63: 655-659. PMID: 38135676, PMCID: PMC11055676, DOI: 10.1111/ijd.16998.Peer-Reviewed Original ResearchObsessive–compulsive disorder among patients with atopic dermatitis: a case–control study in the All of Us research program
Chen G, Fan R, Leasure A, Levey D, Damsky W, Cohen J. Obsessive–compulsive disorder among patients with atopic dermatitis: a case–control study in the All of Us research program. Archives Of Dermatological Research 2023, 316: 11. PMID: 38038754, DOI: 10.1007/s00403-023-02767-3.Peer-Reviewed Original ResearchAssociation between atopic dermatitis and inflammatory bowel disease among US adults in the All of Us Research Program
Joel M, Damsky W, Cohen J, Wride M. Association between atopic dermatitis and inflammatory bowel disease among US adults in the All of Us Research Program. Clinical And Experimental Dermatology 2023, 49: 390-392. PMID: 37967342, PMCID: PMC10957220, DOI: 10.1093/ced/llad397.Peer-Reviewed Original ResearchA bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better
Djureinovic D, Weiss S, Krykbaeva I, Qu R, Vathiotis I, Moutafi M, Zhang L, Perdigoto A, Wei W, Anderson G, Damsky W, Hurwitz M, Johnson B, Schoenfeld D, Mahajan A, Hsu F, Miller-Jensen K, Kluger Y, Sznol M, Kaech S, Bosenberg M, Jilaveanu L, Kluger H. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Molecular Cancer 2023, 22: 182. PMID: 37964379, PMCID: PMC10644655, DOI: 10.1186/s12943-023-01884-x.Peer-Reviewed Original ResearchConceptsStable diseasePartial responseMacrophage populationsThree-drug regimenUnconfirmed partial responsePhase I trialLimited treatment optionsMonocyte/macrophage populationNon-classical monocytesMurine melanoma modelTreatment-related changesResultsThirteen patientsWorse survivalI trialInflammatory tumorPatient populationTreatment optionsImmune cellsDisease progressionMurine studiesPreclinical modelsResistant melanomaAntigen presentationMurine modelCyTOF analysis207 Spatial proteomic and transcriptomic profiling of lichen planus reveals a unique inflammatory architecture
Garritano J, Kidacki M, Cho C, Lopez-Giraldez F, Damsky W, Chen L, Vesely M. 207 Spatial proteomic and transcriptomic profiling of lichen planus reveals a unique inflammatory architecture. Journal Of Investigative Dermatology 2023, 143: s367. DOI: 10.1016/j.jid.2023.09.215.Peer-Reviewed Original ResearchCutaneous Sarcoidosis
Abdelghaffar M, Hwang E, Damsky W. Cutaneous Sarcoidosis. Clinics In Chest Medicine 2023, 45: 71-89. PMID: 38245372, DOI: 10.1016/j.ccm.2023.08.004.Peer-Reviewed Original ResearchMachine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis
Murphy M, Hwang E, Singh K, Lee T, Cohen J, Damsky W. Machine learning analysis of pretreatment skin biopsies predicts nonresponse to dupilumab in patients with eczematous dermatitis. British Journal Of Dermatology 2023, 190: 132-134. PMID: 37818837, DOI: 10.1093/bjd/ljad389.Peer-Reviewed Original ResearchTreatment options for necrobiosis lipoidica: a systematic review
Nihal A, Caplan A, Rosenbach M, Damsky W, Mangold A, Shields B. Treatment options for necrobiosis lipoidica: a systematic review. International Journal Of Dermatology 2023, 62: 1529-1537. PMID: 37772666, DOI: 10.1111/ijd.16856.Peer-Reviewed Original ResearchConceptsTopical calcineurin inhibitorsNecrobiosis lipoidicaTopical corticosteroidsCalcineurin inhibitorsTreatment optionsCase reportJAK inhibitorsSystematic reviewTreatment of NLLimited high-quality evidenceHigh-quality evidenceHigh morbidityCombination therapyRecalcitrant diseaseTreatment modalitiesCompression therapyStandardized endpointsTherapeutic modalitiesClinical careCollagen degenerationTreatment efficacyNew treatmentsLiterature searchTherapyCorticosteroids44140 Obsessive-Compulsive Disorder Among Patients with Atopic Dermatitis: A Case-Control Study in the All of Us Research Program
Chen G, Fan R, Leasure A, Damsky W, Cohen J. 44140 Obsessive-Compulsive Disorder Among Patients with Atopic Dermatitis: A Case-Control Study in the All of Us Research Program. Journal Of The American Academy Of Dermatology 2023, 89: ab69. DOI: 10.1016/j.jaad.2023.07.279.Peer-Reviewed Original Research43437 Ustekinumab for the Treatment of Metastatic Crohn Disease
McKay G, Coromilas A, Liu L, Murphy M, Punyamurthy N, Damsky W, Wanat K, Rosenbach M, Caplan A, LaSenna C, Shields B. 43437 Ustekinumab for the Treatment of Metastatic Crohn Disease. Journal Of The American Academy Of Dermatology 2023, 89: ab103. DOI: 10.1016/j.jaad.2023.07.414.Peer-Reviewed Original ResearchLichen Nitidus: A Case of Tiny, Shiny, Skin Bumps
Kimball K, Damsky W, Richmond J. Lichen Nitidus: A Case of Tiny, Shiny, Skin Bumps. Frontiers For Young Minds 2023, 11: 1033760. DOI: 10.3389/frym.2023.1033760.Peer-Reviewed Original ResearchMolecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis
Hwang E, Abdelghaffar M, Shields B, Damsky W. Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis. JID Innovations 2023, 3: 100220. PMID: 37719661, PMCID: PMC10500476, DOI: 10.1016/j.xjidi.2023.100220.Peer-Reviewed Original ResearchDisease pathogenesisCutaneous granulomatous disordersLow-quality evidenceRepository corticotropin injectionOutcome of treatmentImmunomodulatory medicationsPulmonary sarcoidosisCutaneous sarcoidosisGranulomatous disorderNecrobiosis lipoidicaCorticotropin injectionMacrophage accumulationGranuloma annulareGranulomatous diseaseCutaneous granulomatous diseasesTargeted therapyDrug AdministrationMolecular pathogenesisNew treatmentsSystematic reviewPathogenesisTherapyDistinct diseasesTherapeutic innovationsDiseaseDrug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management
Wei B, Fox L, Kaffenberger B, Korman A, Micheletti R, Mostaghimi A, Noe M, Rosenbach M, Shinkai K, Kwah J, Phillips E, Bolognia J, Damsky W, Nelson C. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. Part II diagnosis and management. Journal Of The American Academy Of Dermatology 2023, 90: 911-926. PMID: 37516356, DOI: 10.1016/j.jaad.2023.02.073.Peer-Reviewed Original ResearchSevere cutaneous adverse reactionsCutaneous adverse reactionsSystemic symptomsDrug reactionsAdverse reactionsDifferential diagnosisDrug-induced hypersensitivity syndrome/drug reactionDrug-induced hypersensitivity syndromeDiHS/DRESSVisceral organ involvementSteroid-sparing agentCornerstone of managementFirst-line therapyEvidence-based overviewSystemic corticosteroidsHypersensitivity syndromeImmediate discontinuationOrgan involvementRisk stratificationAutoimmune diseasesAdjunctive testNeoplastic disordersDiagnostic criteriaLongitudinal evaluationDiagnosis